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OBJECTIVES: In Russia, over 100,000 patients are diagnosed withmultiple sclerosis
(MS), but only about 18,000 patients are on diseasemodifying therapy (DMT) (Gusev
EI et al, 2011). Introduction of newDMT, such as natalizumab, requires a pharmaco-
economic substantiation, to prove its cost-effectiveness in Russian economic
conditions. METHODS: Cost-effectiveness of natalizumab treatment was com-
pared to that of interferon beta-1a IM, interferon beta-1a SC, interferon beta-1b,
and glatiramer acetate, using the cost of an avoided relapse. RESULTS: The cost of
12-month treatmentwith natalizumab is 1,186,176 RUB (37,608 USD), the 12-month
costs of treatment with interferon beta-1a IM, interferon beta-1a SC, interferon
beta-1b, and glatiramer acetate were 459,534 RUB, 797,940 RUB, 532,080 RUB, and
502,073 RUB respectively, using average prices for 2010-2011 (or 14,570 USD, 25,299
USD, 16,870 USD, 16,014 USD). Despite higher cost of course of natalizumab, its
efficacy was higher compared to other DMT. Annual number of avoided relapses
per one patient with relapsing-remitting MS on natalizumab was 1.27 (Polman CH,
et al. 2006). At the same time, for comparable groups of MS patients treated with
interferon beta-1a IM, interferon beta-1a SC, interferon beta-1b, and glatiramer
acetate, the numbers of prevented relapses were 0.61, 0.65, 0.55, and 0,61 respec-
tively (Jacobs LD, et al., 1996; PRISMS Study Group, 1998; The IFNBMS Study Group,
1993; Johnson KP, et al., 1995). The calculated costs of one prevented relapse was
934,000 RUB (29,613 USD) for natalizumab, 753,000 RUB for interferon beta-1a IM
(23,885 USD), 1,227,000 RUB (38,922 USD) for interferon beta-1a SC, 967,000 RUB
(30,672 USD) for interferon beta-1b, and 823,000 RUB (26,096 USD) for glatiramer
acetate. CONCLUSIONS: The cost of one prevented relapse in patient treated with
natalizumab was lower than in patients treated with interferon beta-1a SC and
interferon beta-1b, but somewhat higher than in patients treated with interferon
beta-1a IM and glatiramer acetate.
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OBJECTIVES: Fingolimod has recently been approved for reimbursement in Swe-
den for the treatment of patients with relapsing-remitting multiple sclerosis
(RRMS). Based on its indication, fingolimod will be a new alternative for patients
with RRMS (the population for which natalizumab is also indicated). The objective
is to evaluate the cost-effectiveness of natalizumab compared to fingolimod in
patients with RRMS and a sub-group of patients with rapidly evolving severe (RES)
disease in Sweden. METHODS: The original natalizumab model submitted to the
UK National Institute for Health and Clinical Excellence (NICE) was adapted to
include fingolimod as a comparator treatment and updated with recent epidemi-
ological data from Sweden. The model captures the treatment effect on disability
progression and relapse rate. Only direct medical costs were considered and all
costs were reported in 2011 SEK. The administration cost of fingolimod was con-
servatively assumed to be 0 SEK, while the administration cost of natalizumabwas
7397 SEKper year. Additional costs included drug acquisition andmonitoring costs.
Progressive multifocal leukoencephalopathy (PML) and associated disutility were
incorporated. Quality adjusted life years, life years, and overall cost per patient for
both treatment groups were reported and were used to derive incremental cost-
effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was performed
to test uncertainty around the model parameters. RESULTS: Natalizumab domi-
nated fingolimod (incurs cost savings and additional benefits) in patients with RES
over a lifetime horizon. The ICER was 213,926 SEK in the overall patient group,
which was below the commonly considered ICER threshold (500,000-700,000 SEK)
in health technology assessments in Sweden. PSA showed that over lifetime hori-
zon, the probability of natalizumab being cost-effective at 500,000 SEK threshold
was 89% and 62% in RES and overall patient populations, respectively.
CONCLUSIONS: Natalizumab is a highly cost-effective treatment for both patient
groups with RRMS when compared to fingolimod in Sweden.
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OBJECTIVES: This study reviews cost-effectiveness (CE) evidence of anti-epileptic
drugs (AEDs) in adult patients with epilepsy. METHODS: A systematic literature
search was conducted in Medline from January 1948 through August 2011 using
search terms for seizure, economic analyses and AEDs. Identified studies were
screened based on a priori inclusion criteria. Reference lists of the included articles
were examined to identify additional studies. Information was extracted on: study
design, costs, outcomes, resource and utility data sources, sub-group and sensitiv-
ity analyses, and key findings. RESULTS: Twenty-four studies were included. De-
cision-treemodelingwas used in 14 studies, followed byMarkovmodeling in seven
studies. Nine studies evaluated the CE of AEDs used as monotherapy, whereas 16
studies evaluated adjunctive use of AEDs. Primary outcomes were seizure freedom
in monotherapy studies and 50% reduction in seizure frequency in adjunctive
therapy studies. Ten studies assessed drug tolerability. Only two studies used net-
workmeta-analysis to compare treatment efficacy across trials. No subgroup anal-
yses were identified. Results varied across studies due to divergent methodology;
however, a few themes emerged. For monotherapy in newly diagnosed patients,
first-generation AEDs had lower costs but similar outcomes when compared to
second-generation AEDs such as lamotrigine. When adjunctive therapies were
compared to each other, older AEDs had lower costs but also resulted in lower
quality-adjusted life-year gains compared to the newer AEDs such as tiagabine,
lacosamide and leviteracetam.CONCLUSIONS:There is limited evidence regarding
the CE of newer AEDs in refractory patients. Studies in this population that take
into account efficacy and tolerability are needed.When head-to-head trials are not
available, network meta-analysis should be considered. Additionally, there is no
evidence on the CE of AEDs in subgroups, e.g., patients with complex partial sei-
zures and adolescents.
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OBJECTIVES: To determine the impact of structural sensitivity analysis on conclu-
sions regarding the cost-effectiveness (cost-utility) of pharmaceutical treatments
for Parkinson’s disease in the USA and the United Kingdom using the EQ-5D, HY,
Off-time, PDQ-39, and the UPDRS.METHODS:We built five separate Markov mod-
els (in Microsoft Excel®) for three Parkinson’s disease products using published
clinical data combinedwith costs andutilities obtained frompublished Parkinson’s
disease cost-utility models to determine the sensitivity of cost-effectiveness con-
clusions to different structural assumptions. RESULTS: We found that that using
health states based on the PDQ-39 and UPDRS generated the most favorable cost-
effectiveness ratios for each of the three products (across both countries) while
using the off-time health state definition led to the least favorable results. This is,
perhaps, not surprising since the PDQ-39 and the UPDRS rating scales are Parkin-
son’s disease specific, while the EQ-5D is a generic instrument (PD patients may
have particularly poor recall and consequently report inconsistent or implausible
HR-QoL values when using generic HRQoL instruments). Finally, the extremely
broad nature of the off-time health states led to poorer overall cost-effectiveness
results in addition to significantly increasing overall uncertainty in the results
-reflected by using cost-effectiveness acceptability curves. CONCLUSIONS: We
demonstrate through extensive structural sensitivity analysis that whilst conclu-
sions regarding the sensitivity of results to some key parameters (such as health
state costs andutilities) can be consistent across differentmodel structures, overall
cost-effectiveness can be significantly different (both in terms of expected cost-
effectiveness and the corresponding uncertainty) depending on the structural as-
sumptions made. By ignoring structural sensitivity analysis it is possible to erro-
neously infer that a product may be cost-effective when using a poor choice of
structural assumptions; similarly it is possible to erroneously infer that a product
may be NOT cost-effective even though structural sensitivity analysis demon-
strates this to be unlikely.
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OBJECTIVES: To estimate the economic benefits of slowing Parkinson’s Disease
(PD) progression to Medicare, private insurers, and patients. Recent research dem-
onstrated large societal economic gains from slowing PD progression through
Hoehn and Yahr (H&Y) stages. Herein, we consider economic benefits captured by
Medicare, private insurers, and patients from slowing progression. METHODS: A
previously-developed model was adapted to evaluate net monetary benefits
(NMBs) from a progression rate reduction of 20% toMedicare and patients when PD
diagnosis was made at age 60 and to private payers and patients when diagnosis
was at age 50. Costs were based onMedicare (N25,577 patients) and private payer
(N1,151) claims analyses. Income loss associated with PD-related early retire-
ment was estimated using a published model based on disability claims (N306
employed persons newly diagnosed with PD). Model timeframe was 25 years and
outcomes were discounted at 3% annually. Quality-adjusted life-years (QALYs)
were based on published health utility data and monetized at $50,000. Patients
were 61%male and assumed to begin 50% inH&Y1 and 50% inH&Y2.RESULTS:The
diagnosed at age 60 scenario resulted in cost offsets of $41,207 and QALY gain of
0.50 to Medicare (NMB$66,188 if Medicare values QALY gains). From the 60 year-
old patient perspective, slower progression leads to saving $11,800 due to patient
out-of-pocket payments, $17,979 in additional income due to slower PD-related
early retirement, and $24,981 from QALY gains. The diagnosed at age 50 scenario
resulted in cost offsets of $44,081 and QALY gain of 0.52 to the private payer
(NMB$69,937 if the payer values QALY gains). From the 50-year-old patient per-
spective, slower progression leads to saving $12,236 due to patient out-of-pocket
payments, $69,827 from slower early retirement, and $25,856 due to QALY gains.
CONCLUSIONS: PD costs are substantial from a Medicare, private insurer, and
patient perspective.
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